CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.540
-0.110 (-4.15%)
Jun 4, 2025, 3:54 PM - Market open
CytomX Therapeutics Employees
As of December 31, 2024, CytomX Therapeutics had 121 total employees, including 119 full-time and 2 part-time employees. The number of employees decreased by 1 or -0.82% compared to the previous year.
Employees
121
Change (1Y)
-1
Growth (1Y)
-0.82%
Revenue / Employee
$1,219,479
Profits / Employee
$343,826
Market Cap
400.16M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
CTMX News
- 6 days ago - CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 16 days ago - CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma - GlobeNewsWire
- 22 days ago - CytomX Therapeutics: Doubling Overnight On Phase 1 Data - Seeking Alpha
- 23 days ago - CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript) - Seeking Alpha
- 23 days ago - Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report - Benzinga
- 23 days ago - CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - GlobeNewsWire
- 23 days ago - CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC) - GlobeNewsWire
- 23 days ago - CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire